{"nctId":"NCT00558428","briefTitle":"Telmisartan/Amlodipine (80/5) vs. Telmisartan/Amlodipine (40/5) vs. Amlodipine 10 or 5 in Resistant Hypertension","startDateStruct":{"date":"2007-10"},"conditions":["Hypertension"],"count":1098,"armGroups":[],"interventions":[{"name":"fixed dose combination of telmisartan+amlodipine","otherNames":[]},{"name":"amlodipine","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. patients aged at least 18 years at the date of signing the consent form\n2. diagnosis of essential hypertension and blood pressure not adequately controlled before enrolment in the study\n3. failure to respond adequately to six weeks treatment with amlodipine 5 mg monotherapy\n4. able to stop any current antihypertensive therapy without unacceptable risk to the patient (Investigator's decision)\n5. willing and able to provide written informed consent (in accordance with Good Clinical Practice and local legislation).\n\nExclusion Criteria:\n\n1. are not practising acceptable means of birth control or do not plan to continue using acceptable means of birth control throughout the study and do not agree to submit to pregnancy testing during participation in the trial. Acceptable methods of birth control include the transdermal patch, oral, implantable or injectable contraceptives, sexual abstinence and vasectomised partner.\n2. known or suspected secondary hypertension\n3. mean seated systolic blood pressure (SBP) over 200 mmHg and/or mean seated diastolic blood pressure (DBP) over 120 mmHg at Visit 1 or 2 or mean seated SBP over 180 mmHg and/or mean seated DBP over 120 mmHg at the end of the run-in period (Visit 3)\n4. any clinically significant hepatic impairment (e.g. clinically significant cholestasis, biliary obstructive disorder or hepatic insufficiency)\n5. severe renal impairment (e.g. serum creatinine \\>3.0 mg/dL or \\>265 mcmol/L, known creatinine clearance \\<30mL/min or clinical markers of severe renal impairment)\n6. bilateral renal artery stenosis or renal artery stenosis in a solitary kidney or post-renal transplant\n7. clinically relevant hyperkalaemia\n8. uncorrected volume or sodium depletion.\n9. primary aldosteronism.\n10. hereditary fructose or lactose intolerance","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline in Trough Seated Diastolic Blood Pressure (DBP)","description":"Change from baseline to the end of study in trough DBP","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.71","spread":"0.49"},{"groupId":"OG001","value":"-7.95","spread":"0.49"},{"groupId":"OG002","value":"-9.35","spread":"0.48"},{"groupId":"OG003","value":"-10.63","spread":"0.48"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Trough Seated Systolic Blood Pressure (SBP)","description":"Change from baseline to the end of study in trough SBP","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.18","spread":"0.73"},{"groupId":"OG001","value":"-11.11","spread":"0.72"},{"groupId":"OG002","value":"-13.56","spread":"0.71"},{"groupId":"OG003","value":"-14.99","spread":"0.71"}]}]}]},{"type":"SECONDARY","title":"Trough Seated Diastolic Blood Pressure Control","description":"The number of patients who reach the target DBP of \\<90mmHg","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"107","spread":null},{"groupId":"OG001","value":"148","spread":null},{"groupId":"OG002","value":"153","spread":null},{"groupId":"OG003","value":"173","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"148","spread":null},{"groupId":"OG001","value":"113","spread":null},{"groupId":"OG002","value":"117","spread":null},{"groupId":"OG003","value":"98","spread":null}]}]}]},{"type":"SECONDARY","title":"Trough Seated DBP Response","description":"The number of patients who reach the target DBP of \\<90mmHg or had a reduction in DBP \\>= 10mmHg","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"116","spread":null},{"groupId":"OG001","value":"163","spread":null},{"groupId":"OG002","value":"177","spread":null},{"groupId":"OG003","value":"187","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"139","spread":null},{"groupId":"OG001","value":"98","spread":null},{"groupId":"OG002","value":"93","spread":null},{"groupId":"OG003","value":"84","spread":null}]}]}]},{"type":"SECONDARY","title":"Trough Seated SBP Control","description":"The number of patients who reach the target SBP of \\<140mmHg","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"142","spread":null},{"groupId":"OG002","value":"162","spread":null},{"groupId":"OG003","value":"178","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"155","spread":null},{"groupId":"OG001","value":"119","spread":null},{"groupId":"OG002","value":"108","spread":null},{"groupId":"OG003","value":"93","spread":null}]}]}]},{"type":"SECONDARY","title":"Trough Seated SBP Response","description":"The number of patients who reach the target SBP of \\<140mmHg or had a reduction in SBP \\>= 15 mmHg","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"118","spread":null},{"groupId":"OG001","value":"166","spread":null},{"groupId":"OG002","value":"187","spread":null},{"groupId":"OG003","value":"200","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"137","spread":null},{"groupId":"OG001","value":"95","spread":null},{"groupId":"OG002","value":"83","spread":null},{"groupId":"OG003","value":"71","spread":null}]}]}]},{"type":"SECONDARY","title":"Trough Seated Blood Pressure (BP) Normality Classes","description":"The number of patients who reach predefined BP categories:\n\n* Optimal - SBP\\<120 and DBP\\<80 mmHg\n* Normal - SBP\\<130 and DBP\\<85 mmHg\n* High-normal - SBP\\<140 DBP\\<90 mmHg\n* Stage 1 hypertension - SBP\\<160 and DBP\\<100\n* Stage 2 hypertension SBP\\>=160 and DBP\\>=100 mmHg","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"5","spread":null},{"groupId":"OG002","value":"19","spread":null},{"groupId":"OG003","value":"21","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"23","spread":null},{"groupId":"OG001","value":"30","spread":null},{"groupId":"OG002","value":"35","spread":null},{"groupId":"OG003","value":"51","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"42","spread":null},{"groupId":"OG001","value":"68","spread":null},{"groupId":"OG002","value":"63","spread":null},{"groupId":"OG003","value":"67","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"118","spread":null},{"groupId":"OG001","value":"126","spread":null},{"groupId":"OG002","value":"127","spread":null},{"groupId":"OG003","value":"110","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"70","spread":null},{"groupId":"OG001","value":"32","spread":null},{"groupId":"OG002","value":"26","spread":null},{"groupId":"OG003","value":"22","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Patients With Oedema","description":"Patients from the treated set who experienced at least one case of general oedema.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"23","spread":null},{"groupId":"OG001","value":"76","spread":null},{"groupId":"OG002","value":"14","spread":null},{"groupId":"OG003","value":"10","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"23","spread":null},{"groupId":"OG001","value":"75","spread":null},{"groupId":"OG002","value":"14","spread":null},{"groupId":"OG003","value":"10","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":2,"n":267},"commonTop":["Oedema peripheral"]}}}